Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 4/20 | 0.69 |
| ▸ | ORAI1 | Q96D31 | 4/20 | 0.69 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.69 |
| ▸ | GRM1 | Q13255 | 12/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.40 |
| ▸ | IL2 | P60568 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16018246 | 0.91 | STIM1 (0.56) | STIM1ORAI1ORAI2GRM1GRM4 | |
| SCHEMBL16018201 | 0.87 | STIM1 (0.52) | STIM1ORAI1ORAI2GRM1GRM4 | |
| SCHEMBL16020559 | 0.86 | STIM1 (0.64) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL16018177 | 0.86 | STIM1 (0.66) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL12155798 | 0.84 | STIM1 (0.75) | STIM1ORAI1ORAI2GRM4IL2 | |
| SCHEMBL16018174 | 0.84 | STIM1 (0.64) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL16018198 | 0.83 | STIM1 (0.70) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL12241466 | 0.82 | STIM1 (0.75) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL12155799 | 0.82 | STIM1 (0.69) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL16018181 | 0.82 | STIM1 (0.66) | STIM1ORAI1ORAI2IL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856240-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20140256745-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256745-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.